Oppenheimer initiates coverage of Vylor with Outperform rating and $82 price target
Oppenheimer began research coverage of Vylor Inc., assigning an Outperform rating and a $82 price target. The firm highlighted the company's pure‑play seed and genetics focus, projected 2026 sales of $10.4 billion and EBITDA of $2.8 billion, and noted a 27% EBITDA margin. Management aims for 3‑4% annual sales growth and 7‑8% EBITDA growth through 2029, with licensing expected to turn net positive in 2027. The coverage follows Vylor’s recent spin‑off from Corteva, creating a standalone investment opportunity.
Why it matters
Oppenheimer’s note suggests the stock could rise about 22% from its $73.33 level, offering investors a focused exposure to the seed genetics market. The firm also expects licensing to become a net royalty earner, potentially boosting margins and cash flow. The new coverage may attract additional analyst attention and capital to Vylor.
Key facts
- 1Oppenheimer set a price target of $82.00 for Vylor. investing.com
- 2Vylor’s shares were trading at $73.33 at the time of the report. investing.com
- 3Vylor generated $4.28 billion in EBITDA on $17.81 billion of revenue over the last twelve months. investing.com
- 4Oppenheimer projects 2026 sales of $10.4 billion and adjusted EBITDA of $2.8 billion, implying a 27% margin. tradingview.com
- 5Management targets 3‑4% annual sales CAGR and 7‑8% EBITDA CAGR from 2026‑2029. investing.com
- 6The licensing business is expected to become net positive in 2027. investing.com
Open questions
- Material 5 lists the ticker as CTVA, while other sources use VYLR.
- Other analysts have issued different price targets (Mizuho $84, BofA $78).
Summary written by AlphAI from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.